Core Viewpoint - Bank of America Securities upgraded Huatai Securities (06886) from "Neutral" to "Buy," citing the resolution of uncertainties in fundraising with the issuance of convertible bonds, and maintaining a target price of HKD 22.1, indicating attractive current valuation and robust fundamentals [1] Group 1: Fundraising and Convertible Bonds - Huatai Securities plans to issue HKD 10 billion zero-coupon convertible bonds maturing next year, with a conversion price of HKD 19.7 per share, which corresponds to a price-to-book ratio of 1x for 2024 after excluding dividends [1] - The potential dilution from the full conversion of these bonds is approximately 5.6% [1] - The proceeds from the bond issuance will support the company's overseas business expansion, aligning with the board's previous plan to inject RMB 9 billion into overseas operations [1] Group 2: Financial Outlook and Capital Structure - Bank of America Securities believes that after the bond issuance, the company still has equity financing capacity under general authorization, with a potential issuance scale of up to 20% of total share capital [1] - The firm maintains its earnings forecast for Huatai Securities, indicating confidence in the company's financial stability and growth prospects [1]

Core Viewpoint - Bank of America Securities upgraded Huatai Securities (06886) from "Neutral" to "Buy" due to the resolution of uncertainties in fundraising with the issuance of convertible bonds, maintaining a target price of HKD 22.1, indicating attractive current valuation and stable fundamentals [1] Group 1: Fundraising and Convertible Bonds - Huatai Securities plans to issue HKD 10 billion zero-coupon convertible bonds maturing next year, with a conversion price of HKD 19.7 per share, equivalent to a price-to-book ratio of 1x for 2024 after excluding dividends [1] - The potential dilution from the full conversion of these bonds is approximately 5.6% [1] - The proceeds from the bond issuance will support the company's overseas business expansion, aligning with the board's previous plan to inject RMB 9 billion into overseas operations [1] Group 2: Financial Outlook and Capital Structure - Bank of America Securities believes that after the bond issuance, the company still has room for equity financing under general authorization, with a potential issuance scale of up to 20% of total share capital [1] - The earnings forecast for Huatai Securities remains unchanged, indicating confidence in the company's financial stability and growth prospects [1]

Core Viewpoint - Bank of America Securities reports that Huatai Securities plans to issue HKD 10 billion zero-coupon convertible bonds maturing next year, with a conversion price of HKD 19.7 per share, aligning with the board's previous plan to inject RMB 9 billion into overseas operations [1] Group 1: Bond Issuance Details - The conversion price of HKD 19.7 per share corresponds to a price-to-book ratio of 1x for 2024, excluding dividends [1] - If fully converted, the potential dilution effect is approximately 5.6% [1] - The proceeds from the bond issuance will support the expansion of overseas business [1] Group 2: Financial Implications - Following the bond issuance, the company retains capital financing capacity under general authorization, with a potential issuance scale of up to 20% of total share capital [1] - The completion of this issuance is expected to eliminate uncertainties regarding the company's fundraising efforts [1] Group 3: Investment Rating and Valuation - Bank of America Securities upgrades the investment rating for Huatai Securities from "Neutral" to "Buy" [1] - The current valuation is considered attractive, with a target price set at HKD 22.1 [1] - The company's fundamentals remain robust, and the overseas capital injection may provide upward potential [1]

Core Viewpoint - Hansoh Pharmaceutical (03692) announced the proposed issuance of HKD 4.68 billion zero-coupon convertible bonds maturing in 2033, with all conditions for the bond issuance having been met and successfully implemented on February 3, 2026 [1] Group 1 - The company has received approval for the listing and trading of the convertible bonds on the Hong Kong Stock Exchange [1] - The bonds are expected to be listed and traded on the Vienna MTF operated by the Vienna Stock Exchange on or around February 4, 2026 [1]

Core Viewpoint - Hansoh Pharmaceutical (03692) announced the proposed issuance of HKD 4.68 billion zero-coupon convertible bonds maturing in 2033, with all conditions for the bond issuance having been met and successfully implemented on February 3, 2026 [1] Group 1 - The company has received approval for the listing and trading of the convertible bonds on the Hong Kong Stock Exchange [1] - The bonds are expected to be listed and traded on the Vienna MTF operated by the Vienna Stock Exchange on or around February 4, 2026 [1]

Core Viewpoint - Lenovo Group (00992.HK) submitted a monthly report on share changes to the Hong Kong Stock Exchange, indicating stability in its share structure and compliance with public holding requirements [1] Group 1: Share Capital and Issued Shares - As of January 31, 2026, Lenovo Group's authorized/registered share capital remained unchanged, with a total of 12,404,659,302 issued shares, consistent with the previous month [1] - There are no treasury shares reported, and the company confirms compliance with the applicable public holding requirement, which mandates that at least 25% of issued shares be held by the public [1] Group 2: Convertible Securities - The report updates information regarding convertible securities, specifically noting that 1,150,000,000 warrants issued on January 8, 2025, could potentially increase the share count by 1,187,625,838 shares if fully exercised at an exercise price of HKD 11.92 per share [1] - Additionally, the company issued USD 2,000,000,000 zero-coupon convertible bonds, which could convert into 1,610,618,556 shares at a conversion price of HKD 9.7 per share if fully converted [1]

Core Viewpoint - Hansoh Pharmaceutical (03692) has experienced a decline of over 5%, currently trading at HKD 38.48, with a transaction volume of HKD 69.45 million [1] Group 1: Financial Actions - The company announced a proposal to issue HKD 4.68 billion zero-coupon convertible bonds maturing in 2033, with a conversion price of HKD 57.39, representing a premium of approximately 42.62% over the previous trading day's closing price [1] - The expected net proceeds from the bond issuance are approximately HKD 4.64 billion [1] Group 2: Use of Proceeds - Approximately 65% of the proceeds will be allocated for drug research and development and licensing [1] - About 25% will be used for the construction of new research and development centers and production lines, as well as upgrading existing facilities [1] - The remaining 10% will be designated for working capital and other general corporate purposes [1]

Core Viewpoint - Hansoh Pharmaceutical (03692) has seen its stock price decline over 5%, currently trading at HKD 38.48 with a transaction volume of HKD 69.45 million [1] Group 1: Financial Actions - The company announced a proposal to issue zero-coupon convertible bonds worth HKD 4.68 billion, maturing in 2033, with a conversion price of HKD 57.39, representing a premium of approximately 42.62% over the previous trading day's closing price [1] - The expected net proceeds from the bond issuance are approximately HKD 4.64 billion [1] Group 2: Use of Proceeds - About 65% of the proceeds will be allocated for drug research and development and licensing [1] - Approximately 25% will be used for the construction of new research and development centers and production lines, as well as upgrading existing facilities [1] - The remaining 10% will be designated for working capital and other general corporate purposes [1]

Group 1 - The company, China Ruyi (0136.HK), plans to issue zero-coupon convertible bonds maturing in 2027, amounting to HKD 2.574 billion, with a net amount expected to be approximately HKD 2.548 billion [1] - Approximately 23.27% of the proceeds will be used to repay the group's debts, while about 14.36% will be allocated for acquiring a 30% stake in Beijing Yonghang Technology Co., Ltd [1] - Around 20.02% of the funds will be directed towards strategic investments and acquisitions to expand the group's business, and 15.31% will be utilized for the operational needs of the group's gaming business [1] Group 2 - The initial conversion price of the bonds is set at HKD 2.6 per share, representing a premium of 15.04% over the closing price of HKD 2.26 yesterday [1] - If fully converted, the bonds could convert into approximately 990 million shares, which would represent an increase of about 5.56% in the enlarged share capital [1] - Approximately 27.04% of the proceeds will be used for the production of series on the streaming platform [1]

Core Viewpoint - China Ruyi (00136.HK) has entered into a subscription agreement with Deutsche Bank Hong Kong Branch to issue HKD 2.574 billion zero-coupon convertible bonds due in 2027, which will convert into approximately 990 million shares, representing about 5.89% of the existing issued share capital as of the announcement date [1]. Group 1 - The total principal amount of the bonds to be issued is HKD 2.574 billion [1]. - The net proceeds from the bond issuance are expected to be approximately HKD 2.548 billion after deducting fees, commissions, and other related expenses [1]. - The initial conversion price is set at HKD 2.6 per share [1]. Group 2 - The intended use of the net proceeds includes: - Approximately 23.27% for repaying group debt [1]. - Approximately 14.36% for part of the cost to acquire a 30% stake in Beijing Yonghang Technology Co., Ltd. [1]. - Approximately 20.02% for strategic investments and acquisitions to expand the group's business [1]. - Approximately 15.31% for operational needs of the group's gaming business [1]. - Approximately 27.04% for content production on the streaming platform [1].